Greater harmonisation of clinical trial regulations would help the fight against COVID-19
This brief discusses the existing obstacles in developing international clinical trials that are critical to fight the COVID-19 pandemic. It provides information on relevant adaptations of regulatory requirements for clinical trials, intended to accelerate the processes, and highlights the need to h...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Paris
OECD Publishing
2020
|
| Series: | OECD Policy Responses to Coronavirus (COVID-19)
|
| Subjects: | |
| Online Access: | |
| Collection: | OECD Books and Papers - Collection details see MPG.ReNa |
| Summary: | This brief discusses the existing obstacles in developing international clinical trials that are critical to fight the COVID-19 pandemic. It provides information on relevant adaptations of regulatory requirements for clinical trials, intended to accelerate the processes, and highlights the need to harmonise further these regulations between national regulatory authorities. To this end, this brief describes the existing OECD Recommendation on the Governance of Clinical Trials issued in 2012 and how its implementation could greatly facilitate and streamline the registration and conduct of international clinical trials |
|---|---|
| Physical Description: | 6 p |